Dr Cécile Thomas-Teinturier
Paediatric Endocrinology Service, Bicêtre Hospital/ Inserm CESP (Center for Research in Epidemiology and Population Health) U1018
Tél : 01 45 21 78 52
Researchers from the Paris Public Hospitals (AP-HP), Inserm, the Gustave Roussy and Curie Institutes, and Oscar Lambret Cancer Centre, coordinated by Dr Cécile Thomas-Teinturier of the Paediatric Endocrinology Service at Bicêtre Hospital, have studied the impact of certain therapeutic agents on the fertility of women who have been cured of a paediatric cancer. This research, carried out with support from the French National Cancer League, is published in the journal Human Reproduction on 23 March 2015.
Now that survival is increasing, the impact of therapeutic agents on the future fertility of girls cured of cancer in childhood can affect their quality of life. In all women, the length of reproductive life is related to the number of follicles present in their ovaries, a reserve that cannot be renewed, and that declines over time. Menopause occurs when this number declines below a certain threshold, 5-10 years after the end of fertility.
In this study, the researchers proposed the hypothesis that women who have undergone chemotherapy with a class of drugs known as alkylating agents—cyclophosphamide, ifosfamide, procarbazine—to treat a childhood cancer can have reduced follicular reserve, even though their apparent ovarian function may still be intact (regular cycles).
They evaluated the ovarian reserve in 105 women cured of cancer during childhood, who had received alkylating agents during their childhood, but no radiation therapy in the pelvic area. Investigations included measurement of hormone levels, particularly anti-Müllerian hormone (a reliable marker of ovarian reserve), ultrasound measurement of ovarian size, and follicle count. Results were compared to those for 20 women of the same age who had not received chemotherapy.
The team observed that the 105 women cured of paediatric cancer had smaller ovaries than the untreated women, and a significantly lower level of anti-Müllerian hormone. This reduction was more marked in patients who had received procarbazine for Hodgkin’s lymphoma, or chemotherapy with high doses of alkylating agents prior to a bone marrow transplant. Neither the cyclophosphamide nor ifosfamide dose seemed to be associated with reduced ovarian reserve.
“These results seem to confirm our hypothesis,” explains Dr Thomas-Teinturier. “From a theoretical point of view, the end of fertility is likely to occur earlier in these women who have been cured of a paediatric cancer. This fact, when combined with increasing age at first pregnancy, is likely to increase problems with reproduction.”
However, although assessment of ovarian reserve seems to be a good predictor of the pregnancy rate in infertile women undergoing medically assisted reproduction techniques, there are few data regarding its real use when advising young women cured of paediatric cancer about the potential effects on their fertility, and their risk of early menopause.
“It therefore seems necessary to monitor these markers in this patient cohort in order to define the thresholds that may make it possible to predict the window of fertility and onset of menopause in the following years,” continues Dr Thomas-Teinturier. “The ultimate objective of our study is to be able, in future, to advise these young women individually on their potential for reproduction in the following five years, based on the results of their review at a given moment.”
After 40 years of research, researchers at the CEA, the CNRS, the University of Grenoble-Alps, the University of Montpellier and the Inserm have finally identified the enzyme responsible for the tubulin cycle. Surprisingly, it is not one enzyme but two which control ...
Ovarian reserve after treatment with alkylating agents during childhood
Cécile Thomas-Teinturier1,2,*, Rodrigue Sétchéou Allodji2, Ekaterina Svetlova3, Marie-Alix Frey3, Odile Oberlin3, Anne-Elodie Millischer4, Sylvie Epelboin5, Christine Decanter6, Helene Pacquement7, Marie-Dominique Tabone8, Helene Sudour-Bonnange9, André Baruchel10, Najiba Lahlou11 and Florent De Vathaire2,12
1Department of Paediatric Endocrinology, APHP, Hopital de Bicêtre, rue du Général Leclerc, Le Kremlin Bicêtre F-94270, France
2Radiation Epidemiology Group, Centre for Research in Epidemiology and Population Health (CESP)—INSERM U1018, Institut Gustave Roussy, rue Edouard Vaillant Villejuif F-94805, France
3Department of Paediatric Oncology, Institut Gustave Roussy, rue Edouard Vaillant Villejuif F-94805, France
4Department of Paediatric Radiology, APHP, Hopital Necker, rue de Sevres Paris F-75015, France
5Department of Gynaecology, APHP, Hopital Bichat, rue Henri Huchart, Paris F-75018, France
6Fertility Preservation Unit, Lille University, Hopital Jeanne de Flandre, avenue Eugene Avinee Lille F-59000, France
7Department of Paediatric Oncology, Institut Curie, rue d’Ulm, Paris F-75005, France
8Department of Paediatric Oncology, APHP, Hopital Trousseau, avenue du Dr Arnold Netter, Paris F-75012, France
9Department of Paediatric Oncology, Centre Oscar Lambret, rue Frederic Combemale Lille F-59000, France
10Department of Paediatric Hematology, APHP, Hopital Robert Debre, boulevard Serurier, Paris F-75019, France
11Laboratory of Hormonal Biology, APHP, Hopital Cochin, rue du faubourg Saint-Jacques, Paris F-75005, France
12University Paris-Sud XI, Villejuif F-94800, France
Human Reproduction, 23 march 2015